Pure Global
NCT02582697

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
University of Sydney·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Germ Cell Tumor
Drug/Device/Intervention
Bleomycin (active name: Bleomycin Sulfate)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Sydney
Location
New York,Newcastle,St Leonards,Sydney,Sydney,Sydney,Sydney,Sydney,Sydney,Tweed Heads,Wahroonga,Brisbane,South Brisbane,Woolloongabba,Adelaide,Bedford Park,Hobart,Box Hill,East Melbourne,Heidelberg,St , Australia,New Zealand,United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Feb 01, 2014
End date
Jul 01, 2023
Enrollment
500 participants
Primary outcome

Progression-free survival (disease progression or death)

Summary

The purpose of this study is to determine whether accelerated BEP chemotherapy is more
 effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic
 germ cell tumours.

ICD-10 classifications
Malignant neoplasmsMalignant neoplasm: JejunumMalignant neoplasm: PrepuceMalignant neoplasm: Female genital organ, unspecifiedMalignant neoplasm: Vulva, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02582697
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02582697 through Pure Global AI's free database. This Phase 3 trial is sponsored by University of Sydney and is currently Recruiting. The study focuses on Germ Cell Tumor. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.